Stock Events

Stock Events

Spyre Therapeutics 

€77.50
0
+€0.00+0% 06:00 Today

Statistics

Day High
77.5
Day Low
77.5
52W High
77.5
52W Low
77.5
Volume
-
Avg. Volume
-
Mkt Cap
6.83B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q2 2026
Next
-0.67
-0.55
-0.43
-0.31
Expected EPS
-0.6745906448000001
Actual EPS
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap130.64B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other serious diseases, directly competing in some of the same therapeutic areas as Spyre Therapeutics.
Gilead Sciences
GILD
Mkt Cap178.21B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas such as viral diseases, inflammatory and fibrotic diseases, which overlaps with Spyre Therapeutics' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.46B
Regeneron Pharmaceuticals is known for its innovations in biotechnology, including treatments for rare diseases, which competes with Spyre Therapeutics' efforts in novel therapeutics.
AMGEN
AMGN
Mkt Cap204.01B
Amgen develops biologic therapies, focusing on oncology and cardiovascular diseases, competing with Spyre Therapeutics in the biopharmaceutical sector.
Biogen
BIIB
Mkt Cap32.08B
Biogen focuses on neurological diseases and innovative therapies, which might overlap with Spyre Therapeutics' research and development in similar therapeutic areas.
Incyte
INCY
Mkt Cap24.62B
Incyte Corporation works on small molecule drugs for oncology and inflammation, competing with Spyre Therapeutics in these crucial healthcare segments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.28B
Alnylam Pharmaceuticals develops RNAi therapeutics, a novel approach that could be in direct competition with Spyre Therapeutics' innovative drug development strategies.
Exelixis
EXEL
Mkt Cap13.91B
Exelixis is involved in the discovery, development, and commercialization of new cancer treatments, potentially competing with Spyre Therapeutics in the oncology sector.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.71B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and rare genetic diseases treatments, areas that might intersect with Spyre Therapeutics' interests.

About

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Show more...
CEO
Cameron Turtle
Employees
112
Country
United States
ISIN
US00773J2024
WKN
000A3D4LY

Listings

STU
DE
3920.STU
XNAS
US
SYRE
F
DE
3920.F
MU
DE
3920.MU

0 Comments

Share your thoughts

FAQ

What is Spyre Therapeutics stock price today?▼
The current price of 3920.MU is €77.50 EUR — it has increased by +0% in the past 24 hours. Watch Spyre Therapeutics stock price performance more closely on the chart.
What is Spyre Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Spyre Therapeutics stocks are traded under the ticker 3920.MU.
What is Spyre Therapeutics market cap?▼
Today Spyre Therapeutics has the market capitalization of 6.83B
When is the next Spyre Therapeutics earnings date?▼
Spyre Therapeutics is going to release the next earnings report on November 05, 2026.
What were Spyre Therapeutics earnings last quarter?▼
3920.MU earnings for the last quarter are -0.31 EUR per share, whereas the estimation was -0.66 EUR resulting in a +52.56% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Spyre Therapeutics have?▼
As of September 15, 2026, the company has 112 employees.
In which sector is Spyre Therapeutics located?▼
Spyre Therapeutics operates in the Health & Wellness sector.
When did Spyre Therapeutics complete a stock split?▼
Spyre Therapeutics has not had any recent stock splits.
Where is Spyre Therapeutics headquartered?▼
Spyre Therapeutics is headquartered in WALTHAM, United States.